FOLH1 and metastatic neoplasm: A contemporary cohort may receive PSMA‐PET/CT57 to accurately evaluate local vs metastatic disease recurrence post‐RT, but as this is only a recent clinical development such a cohort with accurate recurrence classifications would lack long‐term follow‐up.